PrEP in Prisons:HIV prevention in incarcerated populations by Parsons, Jordan A & Cox, Chelsea
                          Parsons, J. A., & Cox, C. (2019). PrEP in Prisons: HIV prevention in
incarcerated populations. International Journal of Prisoner Health.
https://doi.org/10.1108/IJPH-09-2019-0053
Peer reviewed version
Link to published version (if available):
10.1108/IJPH-09-2019-0053
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Emerald at https://www.emerald.com/insight/content/doi/10.1108/IJPH-09-2019-0053/full/html. Please refer
to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published




PrEP in Prisons: HIV prevention in incarcerated populations 
Jordan Parsons1 & Chelsea Cox2 
1 Bristol Medical School, University of Bristol, UK 




Purpose: The purpose of this paper is to discuss the possibility of using pre-exposure prophylaxis 
(PrEP) as a HIV harm reduction intervention in prisons. PrEP is primarily discussed in relation to men 
who have sex with men (MSM), meaning other high-risk populations, such as prisoners, are often side-
lined. The authors wanted to consider how it could prove beneficial beyond the MSM community. 
Approach: First, the authors discuss whether the common objections to existing HIV harm reduction 
interventions in prisons, such as needle exchanges, are applicable to PrEP. The authors then apply 
common objections to the provision of PrEP in the general population to the provision of PrEP in a 
prison context in order to assess their strength. Finally, the authors discuss what the authors anticipate 
to be a key objection to PrEP in prisons: post-incarceration access. 
Findings: The authors argue that both sets of common objections considered are easily refuted in the 
case of PrEP in prisons. The unique setting and nature of the intervention are such that it is without 
immediately apparent flaws. In addressing post-incarceration access, the authors suggest that a 
longitudinal consideration of a prisoner’s HIV risk undermines the objection. 
Originality/value: This discussion is of importance due to the significantly heightened risk of HIV 
infection prisoners are subject to. Not only do effective HIV prevention interventions in prisoners 
contribute to fair access to health for incarcerated individuals, but also to the wider fight against HIV. 
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The authors demonstrate that PrEP has potential as a new approach and call for further research in 
this area. 
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Introduction 
Emtricitabine/tenofovir, a form of pre-exposure prophylaxis (PrEP), can significantly reduce the risk of 
HIV infection in individuals who are at high risk. However, it is discussed predominantly in relation to 
the risk of HIV infection from sexual contact within the men who have sex with men (MSM) 
community, even though other high-risk population groups would benefit from access. 
One such population is incarcerated persons. Reports show incarcerated individuals to be 
substantially more likely to be infected with HIV than the general public (Baker, 2018). This is in large 
part due to an overrepresentation of substance dependency in prisoners alongside a lack of accessible 
treatment and harm reduction programmes. The global prison population has grown by 20 per cent 
in the last decade, outpacing population growth, with a substantial proportion of this population 
serving time for drug-related offences (Harm Reduction International, 2018). The need for effective 
and acceptable interventions targeted at those with a drug dependency is evident. 
The World Health Organization (WHO) recommends PrEP for population groups at substantial 
risk of HIV infection (World Health Organization, 2016), and prisoners undoubtedly fulfil this criterion. 
Information that delineates which cohorts would benefit from PrEP consistently includes intravenous 
drug users. In 2017, the WHO highlighted the necessity to ensure that prisoners have access to 
equitable services to reduce the global burden of HIV and AIDS (World Health Organization, 2017). 
The provision of PrEP therapy is one possible mechanism to further the overarching global goal of 
ending AIDS, meriting further engagement and discussion in prison healthcare provision.  
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We present several strong reasons for the provision of PrEP to incarcerated individuals to be 
considered. First, we look to the shortcomings of existing HIV harm reduction efforts in prisons and 
consider their applicability to PrEP. We then take common objections to the provision of PrEP 
generally and assess their relevance in a prison context. Both sets of objections are shown to be 
irrelevant or weak when considering the provision of PrEP in prisons. Finally, we refute the specific 
objection of post-incarceration access to PrEP, thus highlighting the strong justification for the serious 
consideration of the intervention. In doing so, we conclude the need for PrEP discourse to better 
include prison populations.  
 
Needle exchanges 
Currently, the main HIV prevention intervention discussed for prisoners is needle exchange. This has 
existed as an approach since the 1990s, but with limited uptake (Glauser, 2013). Whilst proven both 
cost-effective and successful in reducing the risk of infectious disease transmission, the 
implementation of clean needle exchanges in prisons in various jurisdictions is lacking. This is often 
due to assumptions that providing inmates with clean needles condones drug consumption, is counter 
to prison policies, or could result in weaponization against the staff. Whilst these objections are 
unsubstantiated, alternative and complementary harm reduction programs are needed for those at 
high risk of HIV transmission in prisons. PrEP has the potential to be such an option, avoiding the 
common barriers to the implementation of clean needle exchanges.  
 Needle exchanges in prisons vary in their operational design but are similar in that they 
provide inmates with access to clean needles for the purpose of drug injection. Whilst prison systems 
are viewed as “closed-systems”, drug use is common. Clean needle exchanges act as one harm 
reduction mechanism to address the increased risk of infection from drug use, with their effectiveness 
having been established by decades of research. However, just 60 prisons out of more than 10,000 
worldwide have implemented programmes in the past 20 years (Glauser, 2013). 
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 Rather than needle exchanges, many prisons instead distribute bleach to sterilize drug use 
equipment. Despite its widespread use, bleach distribution has been deemed ineffective in mitigating 
the risk of HIV transmission and is recommended by the WHO only as a second-line strategy (World 
Health Organization et al, 2007). In the hierarchy of harm reduction measures related to drug injection 
and HIV, needle exchanges are considered most effective, with bleach programs providing a 
complementary service but not a replacement. Despite being deemed the better method, clean 
needle exchanges remain scarce. The introduction of PrEP in prisons might address this lack of 
implementation and provide an approach to HIV harm reduction which does not come up against the 
common barriers that needle exchange programmes do.  
 
Condoning and encouraging drug use  
Though intended as a means of harm reduction rather than rehabilitation, needle exchanges have 
been viewed as facilitating and condoning drug use among prisoners by those opposed to their 
implementation (World Health Organization et al, 2007).  There are also concerns that such 
interventions may also condone drug use by prison staff. These beliefs have limited needle exchange 
programme introduction in prisons across the world despite substantial evidence that access to 
sterilized equipment does not result in an increased number of injecting drug users, an increase in 
overall drug use, or an increase in the amount of drugs in prisons (World Health Organization et al, 
2007). This issue has come to fruition most recently in Canada, where two federal pilot programmes 
announced for clean needle exchanges were met with resistance by prison staff and management as 
condoning drug use in prisons (Woo, 2018).  
With over two decades of circular dialogue regarding clean needle programmes as 
encouraging and condoning drug use despite evidence to the contrary, the introduction of PrEP 
therapy has the potential to fulfil the purpose of clean needle programmes whilst avoiding these 
common concerns. A method of HIV harm reduction which utilises medication rather than providing 
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drug use tools better aligns with prison policies and avoids concerns that its introduction directly 
condones drug use. Whilst an ideal scenario which furthers prison health would be the introduction 
of clean needle exchanges, bleach, and PrEP therapy access, the lack of available services over the 
decades suggests that it is optimistic to expect all three.  
Some critics may hold that the provision of PrEP may encourage or condone drug use and is 
therefore counter to prison policies, though we hold that this claim is unsubstantiated. As with other 
harm reduction measures which are criticised for condoning drug use, PrEP is a necessary interim 
strategy in combatting the negative repercussions of substance dependency. Risky drug use will take 
place in prisons regardless of whether clean needles can be accessed and/or PrEP therapy is 
administered. The administration of PrEP therapy does not condone drug use but acts to stem the 
transmission of infectious disease, which minimizes the burden of disease on both the healthcare and 
prison systems.  
The administration of PrEP is fundamentally different from the provision of clean needle 
exchanges and this difference removes the concern of enabling drug use. PrEP is a pill which is taken 
orally. Its administration is not directly connected to the behaviour it seeks to minimize harms from 
(intravenous drug use), which cannot be said for clean needle exchanges. The administration of a pill 
compared to supplying the tools needed to consume drugs is considerably less problematic in terms 
of encouraging drug use and more readily maps onto prison policies than supplying clean needles. 
 
Weaponization of needles  
A further consideration which may position PrEP as a potentially suitable alternative, addressing 
common barriers to clean needle exchanges programmes, is that it cannot be weaponized against staff 
and other inmates. Clean needle programmes have been met with resistance due to fears that access 
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to needles provides inmates with access to a weapon which could endanger prison staff and other 
inmates. 
A WHO review of 55 European prison needle exchanges found no instances of clean needles 
being used as weapons against staff or other inmates (Glauser, 2013). Whilst a thorough analysis of 
all clean needle exchange programmes globally is needed to determine whether these findings are 
consistent across jurisdictions, it highlights the stigmatization that follows clean needle distribution 
programmes. 
This common concern and associated stigma are non-starters in the introduction of PrEP, as 
the pill cannot be weaponised.  
 
Poor uptake 
A final barrier to needle exchange programmes is a lack of uptake by prisoners in those jurisdictions 
where clean needles are available. This issue arises after clean needle programmes have been 
introduced and stems from problems with how clean needles are dispensed to inmates seeking access. 
Prisoners are reluctant to use clean needle exchanges in prisons, as accessing this service can have 
negatives consequences. Accessing this form of harm reduction can result in disciplinary repercussions 
by staff or being flagged in the internal system as a drug user, which can cause further stigmatization 
and negative stereotyping (Jurgens et al, 2009). 
PrEP is unlikely to suffer this fate. As it is a preventative medication rather than a tool used in 
the administration of drugs, taking PrEP does not necessarily suggest drug use in the way requesting 
clean needles does. Whilst further research is needed to determine likely PrEP uptake and 
acceptability in prisons, we believe that barriers to uptake found with needle exchange programmes 




PrEP as harm reduction 
Despite evidence that PrEP is an efficacious drug (Grant et al, 2010; McCormack et al, 2016), it is 
available in only a handful of countries and for few populations. This is for several reasons, which differ 
depending on the population concerned. There are, however, three key objections to PrEP provision 
which are consistently raised: risk compensation, adherence, and cost-effectiveness. We will deal with 
each in turn, demonstrating that all three are likely to be irrelevant where prisoners are concerned. 
 
Risk compensation 
A common objection to the provision of PrEP for those at high risk of HIV is risk compensation. The 
theory of risk compensation supposes that individuals have personal target levels of risk which they 
aim not to exceed (Wilde, 1982). Thus, where an intervention lowers risk, there is room for increased 
risk behaviour. This is individual risk compensation, and in the context of PrEP could mean an increase 
in condomless sex or a decrease in efforts to obtain clean needles, depending on the population group 
concerned. This objection argues that the provision of PrEP is enabling, and perhaps even encouraging, 
negative behaviour. 
There is also an issue with potential community-level risk compensation, or ‘prevention 
optimism’, where PrEP is used to reduce the risk of HIV infection through sexual contact (Holt et al, 
2018). Prevention optimism is where those who are not themselves using PrEP begin to engage in 
riskier behaviour on the assumption that enough other members of the population group are on PrEP; 
these individuals perceive a sort of herd immunity and thus feel safe in increasing their risk. Whilst the 
purpose of the introduction of PrEP in prisons would be for the prevention of HIV infection through 
the use of intravenous drugs, it would also protect inmates against infection through sexual contact. 
It is, then, still important to address this objection. 
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Individual risk compensation is unlikely to be a problem in prison populations as there is little 
room for an increase in risky behaviour among inmates. Those who are intravenous drug users are 
already using dirty needles regularly due to the problems with needle exchange programmes already 
discussed, or because of lack of access to clean needles. 
As for the risk of infection through sexual activity, there is already an issue with access to 
condoms for inmates. Sexual activity is frequently frowned upon in prisons, with prison officers 
attempting to stop it. In the UK, for instance, sexual activity is not prohibited in prisons, but the 
prohibition on sexual activity in public places may be used to deny access to condoms (HM Prison & 
Probation Service, 2018; Howard League for Penal Reform, 2013). Where prisoners have no means to 
access condoms, it is not possible for them to increase their risk by choosing not to use them. The only 
way for sexual risk compensation to take place at the individual level, then, is by prisoners engaging 
in more condomless sex; some may not engage in such activities due to a fear of HIV infection, and 
the availability of PrEP could remove this fear. This is unlikely to be the case for a significant proportion 
of prisoners. In the absence of ready access to condoms, then, PrEP would be a suitable means of 
harm-reduction on this front too. 
Community- and population-level concerns are even less relevant in prison populations. This 
is due to the contained nature of this population group. In the absence of data, it is fair to assume that 
most prisoners would, if presented with the option, choose to take PrEP. This limits the wider 
population that may be affected to the few who choose not to. Whilst it is certainly possible for this 
minority to be affected by prevention optimism, this is not going to noticeably increase their risk of 
HIV infection because they are already at such a high risk and have limited means by which to reduce 
it. 
Risk compensation, then, in the absence of data, does not appear to be a valid objection to 
the provision of PrEP in prisons at the individual-, community-, or population-level. The very high risk 
of HIV-infection prisoners are already at leaves little room for them to increase it through behavioural 
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One thing there is agreement on regarding PrEP is the efficacy of the drug. Studies vary, though PrEP 
is generally believed to > 90 per cent efficacious. However, for this level of protection it is essential 
that users are fully adherent to daily dosing. Whether this is a realistic expectation in real world 
conditions is debated (Myers and Sepkowitz, 2013). 
As debate continues over what level of adherence can be expected of users, so does it over 
the ethical implications of poor adherence. It becomes a harm-benefit calculation; if users are not fully 
adherent they are not getting the intended protection, and where poor adherence and risk 
compensation are found concurrently there is a potential for significant harm to PrEP users (i.e. a 
greater risk of HIV infection than before starting PrEP). 
This is a legitimate ethical concern. To justify an intervention such as PrEP, it is important to 
have strong evidence of effectiveness which, naturally, entails strong adherence in users. In prison 
populations, however, concerns over adherence are irrelevant. 
Concern over poor PrEP adherence arises because PrEP is a daily pill, and some users may 
struggle to get into the habit of taking it. Adherence may prove yet more challenging for those who 
do not have a strong sense of routine in their daily life. The nature of a prisoner’s routine removes this 
concern. Whilst prisoners could not justifiably be forced to take PrEP, it would be a simple task for 
prison staff to provide the daily pill to all inmates at a fixed time each day. Therefore, poor adherence 
in prison populations would be the result of an active choice not to take the pill. 
Both uptake and adherence could be aided by the provision of appropriate information to 
inmates. With the introduction of a PrEP programme in a prison, the benefits of the drug, as well as 
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the side-effects, could be made clear to prisoners so they can make the decision to commence PrEP 
in an informed manner. This would, of course, have to be done objectively to avoid any risk of 
individuals being coerced into commencing PrEP, though it seems reasonable to assume that with 
provision of relevant information uptake would be high. As for the method of deliverance for this 
information, the preferable environment would be an individual consultation with a health care 
professional rather than a group presentation setting so that inmates feel more comfortable asking 
questions.  
 Further research is required to assess likely uptake of PrEP in incarcerated populations, though 
we suggest that it is likely to be high. Of those who do commence PrEP, adherence would not be 
problematic with the assistance of prison staff in addition to education prior to the first dose. The 




Decision-makers inevitably seek financial justification above all else. As such, for PrEP to be introduced 
in prisons it needs to be cost-effective. A full cost-effectiveness analysis is beyond the scope of this 
paper, though we will provide an indication that financial savings are likely. 
 Whilst there is debate over the cost-effectiveness of PrEP outside of prisons, where it would 
be aimed at populations at high risk of HIV infection through sexual contact, existing studies do suggest 
that savings are to be expected (Cambiano et al, 2018). If savings are likely outside of prison, then they 
ought to be greater inside prisons. This is due to the greater prevalence of HIV infection among 
incarcerated individuals; the number needed to treat would be far lower in a prison. There is also the 
fact that savings outside of prisons will be limited by risk compensation and adherence issues, which 
we believe are unlikely to occur in prisons. 
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 Further, with the recent expiration of the patent on Truvada (branded PrEP), a PrEP 
intervention in prisons would benefit from the competitive pricing of generics. This would make the 
financial savings far greater. 
 Where an issue might arise is in responsibility for costs. The lifetime cost of HIV treatment 
would be borne by the healthcare system, whereas the cost of PrEP in prisons may fall to the prison 
system. This could act as a disincentive for prisons to introduce PrEP. It is, however, inappropriate for 
such an issue to present an obstacle to evidence-based healthcare in prisons. Further, it would not be 
an issue in all jurisdictions.  
 It is very likely that the implementation of a PrEP programme in prisons would result in a 
significant financial saving, assuming strong enough uptake and adherence. It is this point that is likely 
to speak most strongly to decision-makers. For that reason, it is important that a more thorough cost-




There is one objection to the provision of PrEP in prisons we anticipate arising, which may make the 
intervention ethically problematic. What happens when a prisoner is released and may no longer have 
access to PrEP? 
 Given the fact that PrEP availability is so limited it is quite likely that if a prisoner had access 
to the drug whilst incarcerated, they would not continue to have access upon release. This applies 
especially to those who are not MSM, as where PrEP is available it is targeted almost exclusively at 
this population. However, this ethical issue is quite easily rebutted. 
 It is important to remember just how much an individual’s risk of HIV infection increases when 
incarcerated. If an individual is an intravenous drug user, they are at a heightened risk of infection 
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relative to the whole population. When incarcerated, the disparity grows yet further. Then, upon 
release, that individual’s risk drops again but remains high relative to the whole population (if that 
individual does not become infected with HIV whilst incarcerated and remains an intravenous drug 
user upon release). 
Let us consider the individual’s risk of HIV before incarceration as the baseline. If PrEP were 
provided to that individual whilst in prison, their risk of infection post-incarceration would not alter, 
but their risk of infection during incarceration would drop significantly; the individual’s risk in prison 
decreases rather than increases, before returning to the baseline. The provision of PrEP in prisons, 
then, does not affect the individual’s risk of HIV infection post-release but can drastically reduce a 
prisoner’s risk whilst incarcerated. Further, providing prisoners with PrEP means they are far less likely 
to be HIV-positive upon release, thus posing a lesser risk to the wider population. 
Post-incarceration access may pose a greater issue if incarceration presented only a small 
increase in the risk of HIV infection, but the increase in risk is too great to allow this objection any 
decisional sway. It is misplaced, therefore, to suggest that the increased risk of infection upon release 
is a valid ethical objection; when account is taken of the situation more broadly, it is quite clear that 
PrEP affords prisoners more benefit than harm even if there is no post-incarceration access. 
  
Conclusion 
HIV is undoubtedly a substantial and immediate concern in the health of prison populations. Whilst 
harm reduction efforts have been made in various countries, infection rates remain significantly higher 
than outside prisons. The natural next step is to explore the potential of PrEP in prisoner care, which 
could be complementary to, and indeed less problematic than, other harm reduction measures whilst 
mapping onto overarching prison policies. This could not only reduce the risk of infection from the use 
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of intravenous drugs, but also condomless sex, whereas previous efforts have been aimed only at the 
former. 
Common objections to the provision of PrEP do not appear to be applicable to prison 
populations; risk compensation cannot take place, adherence is easily monitored in a prison setting, 
and there is good reason to expect financial savings. This is down to the contained nature of 
incarcerated populations and structured environment in which programming takes place. 
If further research does indicate PrEP as effective in a prison setting, provision of the drug 
should not be viewed by justice systems as “ticking the HIV box”. Efforts must continue to address the 
underlying issues, such as rehabilitating inmates with drug dependencies and ensuring that individuals 
access community support upon release. Given the fact PrEP is unlikely to be available to inmates 
following release, rehabilitation is key in ensuring they do not return to a high risk of infection once 
they leave prison. It is also important that PrEP, if provided, be provided as an additional intervention 
and not a replacement. As PrEP protects only against HIV infection, the increased risk of Hepatitis C 
which prisoners find themselves at is not mitigated by the drug. Despite the limited effectiveness of 
existing approaches, such as needle exchanges, they ought not to be discontinued or ruled out if PrEP 
is introduced; even if uptake is minimal, needle exchanges can also protect prisoners against the risk 
of other blood-borne infections. 
Of course, the success of PrEP in prisons rests on uptake and adherence; inmates would need 
to agree to PrEP for it to work. A study to ascertain likely uptake is essential, though in the meantime 
it is reasonable to assume a high proportion would choose to take PrEP if relevant information were 
appropriately provided given the clear benefits it presents.  
Whilst we have not demonstrated that PrEP would be effective in a prison setting – indeed, 
this was not our intention – we have highlighted its potential and thus an important new direction for 
the PrEP debate to take. There are still questions that need to be answered before the implementation 
of PrEP in prisons, and studies are required. Nonetheless, in highlighting the potential of such an 
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intervention and demonstrating the current lack of substantial objections, we have set the ball rolling 
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